Molecular changes consistently associated with neuronal dysfunction/loss—such as APP β-cleavage, and APP and tau phosphorylation—have been widely described [23, 63, 72] in both brains of AD patients and cellular or animal models of the disease. The gene discussed is MAPT; the disease is Alzheimer disease.